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Summary Up to now studies on hypothalamic—pituitary—adrenal (HPA) axis activity in psycho-
sis have shown inconsistent findings. These inconsistencies have been often ascribed to con-
founding effects of long duration of illness and chronic treatment with psychotropic medications
of the subjects studied (chronic psychosis). In the last years, several studies have focused on the
study of subjects at their first episode of psychosis to overcome these possible confounders. The
aim of this paper was to review the literature investigating HPA axis activity in first episode
psychosis. Findings from these studies support the presence of HPA axis hyperactivity and a
blunted HPA axis response to stress at the onset of psychosis. Possible biological pathways linking
these HPA axis abnormalities to the development of psychosis are discussed.
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In the last decades, the vulnerability-stress model has domi-
nated theories on the aetiology and pathogenesis of psychosis
(Walker and Diforio, 1997; Walker et al., 2008; Myin-Germeys
and van Os, 2007). According to this model, predisposing
biological factors increase the sensitivity of some individuals
to stress and thus make them more vulnerable to develop
psychosis under stressful circumstances (Walker and Diforio,
1997; Walker et al., 2008; Myin-Germeys and van Os, 2007).
The study of the hypothalamic—pituitary—adrenal (HPA) axis,
the main biological system involved in the stress response, is
central to reach a better understanding of the biological
mechanisms behind the association between stress and psy-
chosis and leading to the onset of psychosis. HPA axis activity
is activated by the release of corticotropin releasing hormone
(CRH) and of vasopressin (AVP), synthesized in the hypotha-
lamus, which activate the secretion of adrenocorticotropic
hormone (ACTH) from the pituitary, which finally stimulates
the secretion of cortisol from the adrenal gland. Cortisol then
interacts with its receptors in multiple target tissues includ-
ing also the HPA axis, where it is responsible for feedback
inhibition of the secretion of ACTH from the pituitary and
CRH from the hypothalamus (reviewed by Pariante and Light-
man, 2008).
Several previous neuroendocrinological studies have
reported that patients in the acute phase of schizophrenia
or affective psychosis have an elevated basal HPA axis activity
as shown by raised cortisol and ACTH levels, non-suppression
of cortisol secretion by dexamethasone in the dexametha-
sone suppression test, and in the dexamethasone/CRH test
(Sachar et al., 1970; Ryan et al., 2003, 2004b; Tandon et al.,
1991; Lammers et al., 1995; Herz et al., 1985). However,
other studies on patients with chronic schizophrenia have not
found elevated basal cortisol levels or an increased rate of
suppression at the dexamethasone suppression test, espe-
cially if the patients were medicated and clinically stable
(Tandon et al., 1991). Indeed, studying first episode psychosis
patients gives the opportunity to avoid the possible con-
founding effects of long duration of illness and chronic
treatment with psychotropic medications and allows a better
understanding of biological abnormalities at the onset of the
disorder. The aim of this paper was to review the main
findings on HPA axis activity in first episode psychosis and
to discuss the possible implications of HPA axis abnormalities
for the etiopathogenesis of psychosis.
2. Methods
We have performed a systematic search of the literature
using the following sources: PubMed, PsycINFO, Ovid of Med-
line and The Cochrane Library. The key words searched in the
database were using the following search profile: ‘‘CortisolAND first episode psychosis’’ ‘‘Pituitary AND first episode
psychosis’’, ‘‘Cortisol And Schizophrenia’’, ‘‘Pituitary And
Schizophrenia’’. The literature search included papers pub-
lished after 1985 and up to October 2012. Further hand
searches were performed to ensure that all relevant papers
were included. We selected all original papers that measured
cortisol levels or pituitary volumes in patients at first episode
of psychosis and schizophrenia. We excluded studies that
were reporting cortisol levels of already published samples.
Using the titles and abstracts we selected only papers written
in English. From a total of 538 papers, 22 reported cortisol
levels from already published samples, 10 were conference
abstracts and 6 were review articles, and only 16 articles
reached the inclusion criteria and were included in this
review. From a total of 447 papers reporting findings from
studies investigating pituitary volumes in patients with first
episode psychosis and schizophrenia and using the same
criteria as above we included 11 papers.
3. Results
3.1. Studies on cortisol levels in first episode
psychosis
A summary of the studies on cortisol levels in first episode
psychosis is shown in Table 1. The first study investigating
cortisol levels in first episode schizophrenia date back to 1996
(Abel et al., 1996). In this study the authors showed higher
plasma cortisol levels when comparing patients with healthy
controls, suggesting a basal HPA axis hyperactivity in these
patients. All patients, but one, were drug naı¨ve. Only a few
years later, another two studies confirmed higher cortisol
levels in first episode psychosis (Ryan et al., 2003, 2004a). In
particular, Ryan and colleagues assessed plasma cortisol
levels in drug naı¨ve patients with first episode of schizophre-
nia and age- and sex- matched controls, taking a blood
sample at one time-point only during the day (at 8 am after
an overnight fasting). Another three later studies also
reported baseline higher plasma cortisol levels in patients
with first episode psychosis when compared with matched
controls (Walsh et al., 2005; Spelman et al., 2007; Kale et al.,
2010).
However, not all the studies have confirmed high baseline
cortisol levels in first episode psychosis. Indeed, four studies
in drug free/drug naı¨ve or minimally treated first episode
psychosis patients did not find any difference in serum or
plasma cortisol levels collected at one single time point when
compared with age- and sex-matched controls (Strous et al.,
2004; Garner et al., 2011; van Venrooij et al., 2010; Garcia-
Rizo et al., 2012). These inconsistent findings could be
partially due to different methodological procedures.
Indeed, as suggested by other authors (Ryan et al.,
2004b), a procedure based on a single sample for the cortisol
Table 1 Summary of findings from studies investigating cortisol levels in patients with first episode psychosis.
Study FEP
patients
(N)
Healthy
controls
(N)
Measurements details Information on
antipsychotic
treatment in
FEP patients
Findings
Abel et al. (1996) 13 19 Plasma cortisol between
at 08.00 and 09.00
12 drug naı¨ve, 1 on
antipsychotic treatment
Higher cortisol levels
in patients ( p = 0.0059)
Ryan et al. (2003) 26 26 Plasma cortisol at 08.00 All drug naı¨ve Higher cortisol levels
in patients ( p < 0.0001)
Ryan et al. (2004a) 19 19 Plasma cortisol at 08.30 All drug naı¨ve Higher cortisol levels
in patients ( p < 0.003)
Ryan et al. (2004b) 12 12 Plasma cortisol (multiple
time points between
13.00 and 16.00)
All drug naı¨ve Higher cortisol levels
in patients (area under
the curve, p < 0.01)
Strous et al. (2004) 37 27 Plasma cortisol at
08.00—10.00
All drug free No significant difference
Walsh et al. (2005) 10 10 Plasma ACTH and
cortisol at 13.00
All drug naı¨ve Higher cortisol levels
in patients ( p < 0.02)
Ceskova
et al. (2006)
56 No Dexamethasone
suppression test
N/A Decrease in non-
suppression with treatment
Spelman
et al. (2007)
38 38 Plasma cortisol at 08.30 All drug naı¨ve Higher cortisol levels
in patients ( p < 0.001)
Gunduz-Bruce
et al. (2007)
16 No Salivary cortisol
(multiple time-points
during the day and
awakening response)
10 drug naı¨ve 6 on
antipsychotic treatment
(range duration of
treatment: 3—21 days)
Higher cortisol levels
in patients (area under
the curve, p < 0.04)
Hempel
et al. (2010)
27 38 Salivary cortisol (multiple
time-points during the
day and awakening
response)
5 drug free 22 on
antipsychotic treatment
(mean  SD duration
of treatment: from
1  0 to 4.7  3.1 weeks)
Cortisol concentration
decreased more in
patients during the
day in patients
compared with
controls ( p < 0.001)
Kale et al. (2010) 31 48 Plasma cortisol time
not stated
All drug naı¨ve Higher cortisol levels
in patients ( p = 0.005)
Mondelli
et al. (2010a)
50 36 Salivary cortisol (multiple
time-points during the day
and awakening response)
7 drug naı¨ve 43 on
antipsychotic treatment
(range duration of
treatment: 0—119 days)
Higher cortisol levels in
patients with less than
2 weeks of treatment
( p = 0.002). Blunted
cortisol awakening
response in whole
sample of patients
( p = 0.049)
Garner
et al. (2011)
39
(23 f/u)
25 Serum cortisol at 9.00—
10.00 (baseline and
12 weeks follow-up)
14 drug naı¨ve 25 on
antipsychotic treatment
(range duration of
treatment: 0—8 days)
No significant difference at
baseline. Decrease in cortisol
levels over time associated
with symptoms improvement
van Venrooij
et al. (2010)
10 15 Plasma cortisol time not
stated (baseline and
response to stress
challenge)
All drug free No significant difference at
baseline. Blunted cortisol
response to stress
challenge ( p = 0.042)
Garcia-Rizo
et al. (2012)
33 33 Serum cortisol at
8.00—9.00
All drug naı¨ve No significant difference
Pruessner
et al. (2012)
56 30 Salivary cortisol
(at awakening and
30 and 60 min
after awakening)
All on antipsychotic
treatment (mean  SD
duration of treatment:
Male: 8.58  7.75 months
Female: 6.31 
4.37 months)
Blunted cortisol awakening
in patients compared with
controls ( p = 0.023). Blunted
cortisol awakening response
in males compared with
females patients ( p = 0.001),
but not with controls ( p = 0.38)
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an accurate estimate of cortisol levels and of HPA axis
activity.
To overcome this possible limitation, Ryan et al. (2004b),
investigated 12 drug naı¨ve patients with first episode psy-
chosis and 12 age- and sex-matched controls, measuring
plasma cortisol and ACTH levels, collecting blood samples
every 20 min (from 1 pm to 4 pm). In agreement with their
previous studies, patients with first episode schizophrenia
presented higher cortisol and ACTH secretion during the
whole sampling period compared with controls, supporting
the presence of HPA axis hyperactivity in this condition. In
accordance with these findings, two other studies which have
compared saliva samples at multiple time points during the
day (awakening, noon, mid-afternoon and evening) between
drug-naive patients or those with less than three weeks of
antipsychotic treatment, and healthy controls, have found
higher diurnal cortisol levels in patients (Gunduz-Bruce
et al., 2007; Mondelli et al., 2010a). In contrast, the only
other study which collected diurnal salivary cortisol levels at
multiple time points during the day in first episode patients
and controls found that cortisol concentration did not find a
difference in cortisol levels at any specific time point but it
showed steeper decreases in cortisol levels during the day in
patients compared with controls, suggesting a different day-
time sensitivity of the HPA axis (Hempel et al., 2010). Most of
the patients in the latter study were treated with antipsy-
chotic medication.
Other findings, beyond the ones based on basal cortisol
levels, have also supported a role of HPA axis abnormalities in
the pathophysiology of psychosis. Indeed, first episode psy-
chosis patients present a higher cortisol response to meto-
clopramide-induced AVP release than controls, even in
presence of an equal AVP increase, suggesting a greater
pituitary responsiveness to AVP release in psychosis (Walsh
et al., 2005). Moreover, decreases in cortisol levels over time
have been shown to be directly related to improvement in
depression and psychotic symptoms in first episode psychosis,
supporting the involvement of HPA axis activity in the devel-
opment of psychotic symptoms (Garner et al., 2011).
To further understand the role of HPA axis activity in first
episode psychosis, we also conducted a study to test the
dynamic activity of the HPA axis showing that first episode
psychosis patients have a blunted cortisol awakening
response when compared with healthy controls (Mondelli
et al., 2010a). Interestingly these findings were confirmed
by a more recently published study where, however, an
attenuated cortisol awakening response was reported only
in male, but not female, first episode psychosis patients
(Pruessner et al., 2012).
It is important to stress that this is the first time that a
blunted awakening response is described in the context of
higher diurnal cortisol levels. Euthymic or acutely ill patients
with major depression, a condition usually characterized by
elevated cortisol levels during the day (Pariante and Light-
man, 2008), tend to show increased cortisol awakening
response (Bhagwagar et al., 2003, 2005). In contrast, sub-
jects with chronic fatigue syndrome (Roberts et al., 2004),
and post-traumatic stress disorder (Rohleder et al., 2004;
Wessa et al., 2006), conditions usually characterized by
lower cortisol levels during the day (Cleare, 2003; Yehuda,
2001), also tend to show decreased cortisol awakeningresponses (Roberts et al., 2004). This suggests that HPA axis
dysfunction in psychosis is not simply a correlate of depres-
sion or other general psychopathological symptoms but has a
specific profile, perhaps linked to a different genetic back-
ground or a different developmental trajectory of the stress
abnormalities.
The cortisol awakening response is indeed considered a
reliable measure for the acute reactivity of the HPA axis, and
the finding of blunted cortisol awakening response appears in
agreement with a recent study reporting a blunted cortisol
response to a psychological stress (public speaking) in first
episode psychosis (van Venrooij et al., 2010), further support-
ing an abnormal HPA axis response to stress in this condition.
Interestingly we have also recently shown that a more blunted
cortisol awakening response is associated with a worse cogni-
tive functioning in first episode psychosis, and in particular
with a more severe deficit in verbal memory and processing
speed (Aas et al., 2011). Moreover, the cortisol awakening
response has been also found to be associated with clinical
symptoms in first episode psychosis (Belvederi et al., 2012). In
particular, in patients with first episode of schizophrenia, the
cortisol awakening response appeared to be mainly predicted
by the severity of positive symptoms. In contrast, in those with
depressive psychosis, the cortisol awakening response was
instead predicted by excitement, disorganization and depres-
sive symptoms (Belvederi et al., 2012).
Furthermore, some studies are now extending the findings
of an attenuated cortisol awakening response with first
episode of psychosis to possible links with exposure to early
adversity (Pruessner et al., 2012), and thus indicating a
possible neurobiological mechanism in support of the growing
and robust findings that childhood adversity leads to an
increased risk of developing psychosis (Varese et al., 2012).
Only one study investigated the cortisol response to the
dexamethasone suppression test in patients with first episode
schizophrenia; the authors studied patients at the time of
admission to hospital (before starting antipsychotic treat-
ment), at the time of discharge, and again after 1 year and
did not have a comparison group of healthy controls (Ceskova
et al., 2006). The rate of non-suppression was 17.9% at
baseline before starting the treatment, 5.3% at the time
of discharge, and 16% after one year (Ceskova et al., 2006). In
agreement with the literature in chronic schizophrenia, rates
of dexamethasone non-suppression are higher in drug-free
and unmedicated patients. The increase in the rate of non-
suppression after 1 year is explained as a possible conse-
quence of clinical deterioration and of non compliance with
treatment (Ceskova et al., 2006).
3.2. Studies on pituitary volume in first episode
psychosis
The pituitary gland plays an important role in the regulation
of the HPA axis. The volume of the pituitary gland can change
in size as a consequence of both physiological and patholo-
gical alterations in the patterns of hormone secretion. Inter-
estingly, in major depression, HPA axis hyperactivity has been
linked to an increased volume of the pituitary gland (Axelson
et al., 1992).
A summary of the studies on pituitary volume in first
episode psychosis is shown in Table 2. Four of the studies
Table 2 Summary of findings from studies investigating pituitary volumes in patients with first episode psychosis compared with
healthy controls.
Study FEP patients (N) Healthy controls (N) Findings
Pariante et al. (2004) 24 51 Patients > controls
Pariante et al. (2005) 78 78 Patients > controls
MacMaster et al. (2007) 16 12 Increase in pituitary volume at 12 months follow-up:
Patients > controls
Upadhyaya et al. (2007) 51 55 Patients < controls
Garner et al. (2009) 42 No Larger pituitary volume associated with less
improvement in overall psychotic symptoms
at 12 weeks follow-up
Nicolo et al. (2010) 73 48 No difference between patients and controls
Buschlen et al. (2011) 23 20 Patients > controls
Takahashi et al. (2011) 18 20 Patients > controls at baseline and follow-up.
Pituitary enlargement over time: patients > controls
Gruner et al. (2012) 55 59 No difference between patients and controls
Habets et al. (2012) 10 32 Though not significant, patient group had larger
pituitary volumes than controls
Klomp et al. (2012) 26 156 No difference between patients and controls
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episode psychosis report a larger pituitary volume in patients
when compared with healthy controls, further supporting the
presence of HPA axis hyperactivity at the onset of psychosis
(Pariante et al., 2004, 2005; Buschlen et al., 2011; Takahashi
et al., 2011). However, other studies reported smaller or no
significant difference in pituitary volume between first epi-
sode psychosis and healthy controls (MacMaster et al., 2007;
Nicolo et al., 2010; Gruner et al., 2012; Klomp et al., 2012;
Habets et al., 2012).
A possible explanation for these inconsistent findings
(with the exception of Nicolo et al., 2010; Habets et al.,
2012), is that in contrast to the studies above, these studies
assessed patients with first episode of schizophrenia (Mac-
Master et al., 2007; Gruner et al., 2012; Klomp et al., 2012),
whom by definition are likely to have a longer duration of
illness. Habets et al. (2012) compared pituitary volume
between those with an illness duration of less than five years
(FEP), those with an established psychosis, and healthy con-
trols, and found that first episode patients had increased
pituitary volumes compared with controls, whom in turn had
increased pituitary volumes compared with those with an
established illness, though these differences were not sta-
tistically significant, which may have been due to the small
sample size employed (N = 10 in both patient groups).
Indeed, a longer duration of illness has been suggested to
be associated with a reduction in pituitary volume possibly
due to an exhaustion of the HPA axis activation (Upadhyaya
et al., 2007; Pariante et al., 2004).
Another consideration that should be made, and possible
explanation for the inconsistent findings is that the use of
antipsychotic medications has been found to influence pitui-
tary volume, possibly by the stimulation of prolactin secret-
ing cells. Prolactin-enhancing antipsychotics have been
shown to be associated with a larger pituitary volume (Par-
iante et al., 2005; MacMaster et al., 2007; Pariante, 2008),
whilst a longitudinal study has demonstrated that prolactin-
sparing medications reduced pituitary volume over time in a
dose-response manner (Nicolo et al., 2010). Therefore, pitui-
tary volume increases associated with long duration of illnessmay become undetectable if combined with the use of
prolactin-enhancing medication.
Studies conducted so far in psychosis, clearly suggest that
pituitary is a dynamic organ, which changes according to
different stages of the psychotic disorder, in response to both
the disorder itself, and the treatment with antipsychotics.
Specifically, as previously suggested (Pariante, 2008) the
pituitary volume increases during the prodromal phase lead-
ing to psychosis onset (Garner et al., 2005), and it is larger (by
10—20% compared to controls) if assessed during the first 12
months after the psychosis onset (Pariante et al., 2004, 2005;
Takahashi et al., 2011). This effect is not due to antipsychotic
treatment, as it is present in antipsychotic-naı¨ve prodromal
subjects (Garner et al., 2005) as well as in neuroleptic-free
patients with first episode psychosis (Pariante et al., 2005;
Buschlen et al., 2011), and it is likely to reflect HPA axis
hyperactivity.
Interestingly, the pituitary volume is larger in people at
high risk of developing psychosis closer to the psychosis
onset, suggesting not only that HPA axis hyperactivity is
present already before the onset of psychosis, but that this
can also predict subjects who will make the transition to
psychosis (Garner et al., 2005). These findings have been
recently supported by another study, which showed larger
pituitary volume in first episode psychosis patients and in
subjects at high risk of developing psychosis, who later on
developed psychosis, when compared with healthy controls
or with high-risk subjects who did not make transition to
psychosis (Buschlen et al., 2011). Moreover, a more recent
study in drug naı¨ve first episode psychosis patients found that
a larger pituitary volume at onset is associated with less
improvement in psychotic symptoms after 12 weeks of anti-
psychotic treatment (Garner et al., 2009), whilst greater
pituitary enlargement over three years has been associated
with less improvement of psychotic symptoms at follow-up
(Takahashi et al., 2011), further supporting the role of HPA
axis hyperactivity in clinical outcome of these patients.
In summary, preliminary evidence would suggest that
enlarged volumes of the pituitary gland is associated
with increased vulnerability of psychosis, and an enlarged
608 S. Borges et al.pituitary compared to control samples is exhibited in indivi-
duals shortly after psychosis onset. However, the pituitary
gland is evidently a highly dynamic organ, and the reported
inconsistencies in the findings of pituitary volume in first
episode psychosis samples may be related to the heterogeneity
of the samples in terms of illness duration, the type of anti-
psychotic drug prescribed, and state-related impairments.
4. Discussion
This systematic review highlights that converging evidence
exists to suggest that individuals with a first episode of
psychosis show a specific pattern of HPA axis hyperactivity,
demonstrated by higher baseline cortisol levels compared
with controls, and a blunted cortisol awakening response.
Moreover, MRI studies demonstrate that these individuals also
exhibit an enlarged pituitary in comparison to healthy con-
trols shortly after psychosis onset, supporting HPA axis hyper-
activity in this sample.
4.1. HPA axis hyperactivity: a consequence of
illness onset, or a vulnerability marker?
The question remains however whether the abnormal HPA axis
response to stress in first episode psychosis samples is caused
by the onset of the disorder, due to the stressful nature of the
psychotic experiences or an effect of the stressful experience
of being hospitalised, or alternatively, whether the enhanced
stress response exists prior to illness onset, and represents a
marker of biological vulnerability. Several lines of preliminary
evidence point to the latter hypothesis.
Studies of the biological response in individuals at Ultra
High Risk for psychosis allow for an investigation of whether
abnormal HPA axis response to stress exists prior to illness
onset whilst reducing the confounds associated with hospi-
talisation. Increasing evidence suggests that within those at
risk for psychosis, higher levels of cortisol is associated with
prodromal and/or psychotic symptoms (Mittal and Walker,
2011; Corcoran et al., 2012), and as already highlighted, a
larger pituitary at baseline in those at risk is predictive of
later transition to illness (Garner et al., 2005; Buschlen et al.,
2011). Moreover, in support of findings from first episode
psychosis samples, research has found alterations in HPA axis
function in those with Schizotypal Personality Disorder (SPQ;
Mitropolou et al., 2004; Mittal et al., 2007) and in healthy
individuals rating highly on schizotypal traits (e.g. Hori et al.,
2011), thereby reducing the confounds associated with hos-
pitalisation, medication, and the psychosocial consequences
of psychiatric diagnoses (Mednick and McNeil, 1968).
Lastly, as reviewed by Aiello et al. (2012), within indivi-
duals at genetically high risk of psychosis (i.e. in unaffected
relatives of patients with psychosis), studies have shown
increased ACTH blood levels in response to stress (Brunelin
et al., 2008), as well as increased cortisol levels at baseline
and in response to negative daily stress (Collip et al., 2011).
Interestingly, we have found that also first-degree relatives
of patients with schizophrenia present larger pituitary
volume compared with controls (Mondelli et al., 2008).
Though studies of HPA axis activity are limited in number,
these results suggest a familial, possibly genetic, vulnerabil-
ity to hyper-activity of the HPA axis in schizophrenia.4.2. The link between HPA axis and onset of
psychosis
To understand how abnormalities in the HPA axis might be
involved in the onset of psychosis, we will discuss some of the
main relevant biological pathways influenced by HPA axis
activity and how these might play a role in the development
of psychotic symptoms. One of the most relevant mechanisms
to understand the link between HPA axis activity and onset of
psychosis is the synergistic relation between glucocorticoids
and dopamine. Indeed, the notion that the dopaminergic
system is involved in the development of psychotic symptoms
is well established. Interestingly, previous studies have
showed that glucocorticoid secretion augments dopamine
activity in certain brain regions, especially the mesolimbic
system (reviewed by Walker et al., 2008). The molecular
mechanisms behind this effect are still unclear, and are
currently a focus of research, especially in animal models.
Another possible mechanism involved in the association
between HPA axis abnormalities and onset of psychosis
involves the studies finding a blunted HPA axis response to
stress (Mondelli et al., 2010a; van Venrooij et al., 2010). Even
in the presence of HPA axis hyperactivity during the day, the
impaired activation of HPA axis in critical stressful situations
could represent one of the mechanisms leading to the devel-
opment of psychopathology. According to Roelofs et al. (2007),
a blunted cortisol response to acute stress may compromise
optimal cognitive performance and approach-avoidance beha-
viour in situations where it may be important to function
maximally. Moreover, cortisol has been reported to blunt
sympathetic nervous system responses activated by stress in
humans (Raison and Miller, 2003). Interestingly, although cor-
tisol response to psychological stress was blunted in first
episode psychosis, the sympathetic nervous system response
to stress has been shown to be preserved in the same subjects
(van Venrooij et al., 2010). Therefore, it is possible to suggest
that, in presence of a stressful condition, the lack of cortisol
response cannot restrain the activation of the sympathetic
nervous system, resulting in a persistent increased arousal and
a consequent exacerbation of psychotic symptoms.
Glucocorticoids can also influence neuroplasticity
(decreasing neurogenesis and remodelling neuronal den-
drites), affecting neurotrophins levels, such as BDNF, and
through their interaction with pro-inflammatory cytokines,
excitatory amino acid neurotransmitters and NMDA receptors
(reviewed by McEwen, 2000). This is particularly important
since a number of studies have shown brain volume changes
at the onset of psychosis, or during the transition to psycho-
sis, suggesting a critical role for neuroplasticity, especially in
specific brain areas, in the development of psychosis (Taka-
hashi et al., 2009; Cahn et al., 2009). Indeed, we have
recently shown that high cortisol levels are associated with
smaller hippocampal volume in first episode psychosis,
further supporting also this possible biological pathway to
explain the link between HPA axis hyperactivity and onset of
psychosis (Mondelli et al., 2010b, 2011).
4.3. Methodological considerations
4.3.1. Cortisol collection
Cortisol levels vary during the day, reaching the zenith at the
awakening time in the morning, and decreasing in the late
HPA axis activity in first episode psychosis 609afternoon and evening. Unfortunately most of the studies
reviewed in this paper measured cortisol levels using a single
sample of plasma, which does not take in account the
circadian variability of cortisol and might have also been
confounded by an increase in cortisol due to the pain/distress
of the injection (Kirschbaum and Hellhammer, 1994). Mea-
suring cortisol from saliva has been proposed as the method
of choice in stress research as it avoids potential variations
due to the stress of blood drawing procedures, and it allows
collection at multiple time points during the day without an
invasive procedure (Hellhammer et al., 2009).
Only few studies have until now assessed cortisol levels at
multiple time points during the day in first episode of psy-
chosis (Ryan et al., 2004b; Gunduz-Bruce et al., 2007; Hem-
pel et al., 2010; Mondelli et al., 2010a; Pruessner et al.,
2012). One of these studies have shown a steeper decrease in
cortisol levels during the day in first episode psychosis,
further highlighting the importance of studying cortisol diur-
nal rhythm in these patients (Hempel et al., 2010). Recent
studies have also suggested that time of awakening could
affect the extent of the cortisol awakening response, and
therefore this should be taken into account in future studies
assessing cortisol awakening response (Pruessner et al.,
2012).
4.3.2. Effect of medication on cortisol levels
Most of the studies assessing cortisol levels in first episode
psychosis were conducted in drug naı¨ve or medication free
patients (Abel et al., 1996; Ryan et al., 2003, 2004a,b; Strous
et al., 2004; Walsh et al., 2005; Spelman et al., 2007; Kale
et al., 2010; van Venrooij et al., 2010; Garcia-Rizo et al.,
2012). However, five of the reviewed studies included
patients treated with antipsychotic medications. Since the
duration of antipsychotic treatment and the type of anti-
psychotic differed across the subjects in the same study as
well as across the different studies, it is difficult to draw any
definitive conclusion on the effect of antipsychotic treat-
ment on cortisol levels in first episode psychosis.
Indeed, previous studies in patients with chronic schizo-
phrenia have shown that both first and second generation
antipsychotics affect cortisol levels, and increasing evidence
suggests that second generation antipsychotics reduce cor-
tisol to a greater extent than first generation ones (Zhang
et al., 2005; Popovic et al., 2007; Jakoveljevic et al., 2007;
Tanaka et al., 2008). Interestingly, second generation, but
not first generation, antipsychotics have also been shown to
significantly reduce cortisol levels in healthy controls, sug-
gesting that this effect may precede, or be independent
from, the effect of the antipsychotic medication on the
psychotic symptoms (Cohrs et al., 2006). Future longitudinal
studies are needed to clarify the effect of antipsychotic
treatment, as well as possible effect of hospitalization, on
HPA axis activity in first episode psychosis, and its possible
relationship with the clinical outcome.
5. Conclusions
In summary, the onset of psychosis is characterized by HPA
axis hyperactivity, as supported by findings of high cortisol
levels and larger pituitary volume. Our and other authors’
findings also suggest a blunted HPA axis response to stress infirst episode psychosis. Both these abnormalities could play a
relevant role not only in the development of psychosis,
through their effect on the neurotransmitter systems as well
as on neurogenesis. Further study of HPA axis activity in first
episode psychosis is needed not only to help us in getting a
clearer understanding of ethiopathogenesis of this serious
condition, but, more importantly, to facilitate, in the future,
the design of prevention strategies as well as the develop-
ment of novel treatment strategies for individuals affected
by psychosis.
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